title: High-risk stage II colon cancer after curative resection.
abstract: OBJECTIVE
  This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT).
  
  
  METHODS
  We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection.
  
  
  RESULTS
  Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19-9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA)19-9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not.
  
  
  CONCLUSIONS
  ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors.
authors.affiliation: The Japanese Study Group for Postoperative Follow-up of Colorectal Cancer, Japan. harsato@fujita-hu.ac.jp
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Koutarou
authors.initials: K
authors.lastname: Maeda
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Mochizuki
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kotake
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Teramoto
authors.forename: Shingo
authors.initials: S
authors.lastname: Kameoka
authors.forename: Yukio
authors.initials: Y
authors.lastname: Saito
authors.forename: Keiichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Hirai
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohue
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Sakai
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirata
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Hatakeyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate